Shigeyuki Chaki

Toshima, 1708633, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 84 publications

The preclinical profiles and the clinical efficacy and safety of vornorexant (Vorzzz® tablets), a new orexin receptor antagonist

The preclinical profiles and the clinical efficacy and safety of vornorexant (Vorzzz® tablets), a new orexin receptor antagonist

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica

Published: May 06, 2026

Dual orexin receptor antagonists in insomnia: Toward a new therapeutic paradigm.

Dual orexin receptor antagonists in insomnia: Toward a new therapeutic paradigm.

Journal: Pharmacology, biochemistry, and behavior

Published: October 10, 2025

Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant.

Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant.

Journal: The international journal of neuropsychopharmacology

Published: July 09, 2025

Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist.

Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist.

Journal: The Journal of pharmacology and experimental therapeutics

Published: February 24, 2025

Orexin receptors: possible therapeutic targets for psychiatric disorders.

Orexin receptors: possible therapeutic targets for psychiatric disorders.

Journal: Psychopharmacology

Published: February 06, 2025

Melanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics.

Melanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics.

Journal: Pharmacology, biochemistry, and behavior

Published: May 30, 2024

Role of mGlu receptors in psychiatric disorders - Recent advances.

Role of mGlu receptors in psychiatric disorders - Recent advances.

Journal: Pharmacology, biochemistry, and behavior

Published: September 21, 2023

Ketamine and its metabolites: Potential as novel treatments for depression.

Ketamine and its metabolites: Potential as novel treatments for depression.

Journal: Neuropharmacology

Published: March 08, 2023

mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.

mGlu2/3 receptor antagonists for depression: overview of underlying mechanisms and clinical development.

Journal: European archives of psychiatry and clinical neuroscience

Published: November 20, 2022

Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.

Antidepressants in the post-ketamine Era: Pharmacological approaches targeting the glutamatergic system.

Journal: Neuropharmacology

Published: October 28, 2022

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents.

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents.

Journal: The international journal of neuropsychopharmacology

Published: July 16, 2021

Vasopressin V1B Receptor Antagonists as Potential Antidepressants.

Vasopressin V1B Receptor Antagonists as Potential Antidepressants.

Journal: The international journal of neuropsychopharmacology

Published: October 19, 2020

Showing 1-12 of 84

Last Updated: 09/26/2026